Ms. Julia Becker reports

VESALIUS LONGEVITY LABS CLOSES STRATEGIC FINANCING OF US$6.5 MILLION, LED BY INVESTOR GROUP ORGANIZED BY HARVEY SPEVAK

Vesalius Longevity Labs Inc. (formerly Sweet Earth Holdings Corp.) has completed a non-brokered private placement of 6,190,475 units of the company at a price of $1.05 (U.S.) per unit, for aggregate gross proceeds of $6,499,998.75 (U.S.).

The strategic financing was led by a group organized by Harvey Spevak, an investor and visionary leader in global wellness, lifestyle and hospitality, and chairman of Equinox Group. With more than three decades of experience building and scaling distinctive consumer brands, Mr. Spevak is recognized for his brand-focused, consumer-centric approach to innovation, growth and long-term value creation.

The financing led by the investor group organized by Mr. Spevak marks a significant milestone for Vesalius as the company scales its global longevity platform. Mr. Spevak's backing is a strong vote of confidence in Vesalius's vision to close the gap between longevity science and clinical practice. It also validates the company's prescriber-led, quality-first model, which connects licensed health care providers with peptide therapeutics globally. With this injection of capital, Vesalius is well positioned to expand its sales team, enter new markets and help meet growing demand for safe, regulated access to longevity therapies.

"I believe longevity represents one of the most exciting opportunities in health and wellness over the coming decade," said Mr. Spevak. "Vesalius has an ambitious vision for building a differentiated platform. I'm excited to partner with the team and bring my experience in building consumer-focused brands, driving innovation and creating long-term value to help shape the company's next phase of growth."

Each unit consists of one common share in the capital of the company and one-half of one company share purchase warrant, with each whole warrant exercisable to acquire one additional company share at a price of $2.25 (U.S.) for a period of two years from the closing date. The warrants are subject to an acceleration right in favor of the company, which may be exercised by written notice to warrantholders if the volume-weighted average trading price of the common shares on a recognized stock exchange is at or above $3.50 (Canadian) for any 20 consecutive trading days, in which case the expiry date of the warrants will be accelerated to a date not less than 60 days following the date of such notice.

The securities issued pursuant to the offering are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.

About Vesalius Longevity Labs Inc.

Vesalius Longevity Labs is a longevity science and regenerative health platform focused on peptides, biologics, preventative health care and performance optimization. Vesalius operates a scalable business-to-doctor-to-consumer ecosystem designed to support health care providers, telehealth infrastructure, product fulfilment and advanced longevity therapeutics across global markets. Vesalius's expanding ecosystem includes peptide therapeutics, regenerative medicine initiatives, royalty-generating biologics partnerships and advanced provider enablement technologies designed to support the future of personalized health and wellness.

We seek Safe Harbor.